Editorial: FDA restrictions threaten legacy drugs

The FDA in June began to mandate that unapproved legacy drugs, such as quinine, must undergo the same approval process that new drugs go through as part of the agency's new strategy to improve drug safety. These types of longstanding drugs could be withdrawn for the market unless they submit to the FDA's expensive new drug application process, leading The Wall Street Journal to call for the FDA to give them a "special regulatory pathway" for approval.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA